BioGlue (CryoLife Inc, Kenneswa, GA, USA), a bovine serum albumin-glutaraldehyde tissue sealant, was at times used to seal the myocardial holes of the polypropylene stitches at the apex of the heart during transapical aortic valve implantation (TAVI). We describe three patients who developed late wound healing problems after TAVI that were thought to be caused by BioGlue. The surgical wound revision was performed on the 115th, 41st and 60th days, respectively, after original TAVI procedures. At revision, a 'foreign body' reaction surrounded by healthy well-vascularized tissue was found. All intraoperative cultures were sterile despite evidence of purulent-like material at the time of wound debridement. The wounds healed 'per primam intentionem' and the patients' postoperative course was also completely uneventful.
Introduction
Transapical aortic valve implantation (TAVI) is usually an easy and straightforward procedure. Although rare, difficulties in obtaining adequate hemostasis from the apex of the heart are dangerous and life-threatening [1] . This problem can occur in all patients undergoing TAVI but especially in nonagenarians with fragile myocardium, patients who received clopidogrel, aspirin or anticoagulants preoperatively, and those who had previous myocardial infarction and thin anterior left ventricular wall. The key factor is strictly a fragile apical muscle and therefore we do not stop clopidogrel or similar medication before the procedure. Therefore, after good surgical hemostasis of the apex is achieved in TAVI patients, the puncture site may be additionally sealed by local application of biological glue, such as BioGlue (CryoLife Inc, Kennesaw, GA, USA).
BioGlue is a bovine serum albumin-glutaraldehyde tissue sealant. When applied to the surgical site it polymerizes within 20-30 s and reaches its bonding strength within 2 min. BioGlue has been used to seal pulmonary air leaks, to repair splenic injury, in urological and abdominal surgery, and in cardiothoracic surgery, especially for gluing the aortic base in acute aortic dissection [2] [3] [4] . We describe three patients who developed late wound healing complications after TAVI that we thought were an allergic reaction to BioGlue.
Patients
Three patients underwent TAVI and developed late wound complications after initial uneventful course. The patients received surgical revision on the 115th, 41st and 60th days, respectively, after original TAVI procedures. Two of them had purulent-like drainage from a small cutaneous fistula and one had localized swelling and fluctuation in the region of the wound. The TAVI procedures were performed in a hybrid operating room under completely sterile conditions as for standard cardiovascular surgery [5, 6] . At times, biological glue was used to seal the myocardial holes of the polypropylene stitches (pledgeted with equine pericardium or, rarely, with Teflon) at the apex of the heart. This depended on the surgeon's preference. BioGlue was applied in 36 (9.5%) of our 380 TAVI patients. The wound problems appeared about one week before surgical revision, starting with localized wound swelling in all and then followed by wound secretion from a small cutaneous fistula (in the two first patients). This was initially thought to be from a remaining knot of the single resorbable sutures closing the thoracic wall but it persisted. No patient had fever, and leukocytes and CRP values were within the normal ranges. Superficial wound bacteriology before revision was negative in one patient, one had Pseudomonas fluorescens and one skin flora (Table 1) . After several days without improvement by antibiotic (Table 1) Fig. 1a ). Red arrow, aortic valve prosthesis. CT, computed tomography.
Case Report can produce a 'foreign body' reaction [8] . This reaction might persist as long as the glue is locally present. BioGlue remains in situ much longer then other sealants. It degrades via proteolysis and is resorbed slowly, mostly due to albumin being its major component [9] . Therefore, it has been thought that its prolonged inflammatory response caused late complications as an anastomotic aortic pseudoaneurysm. When applied in the deep thoracic structures BioGlue may produce a sterile reaction, e.g. reported mediastinal cyst after BioGlue application in the chest [10] .
It is important to emphasize that a possible reason for this adverse reaction is improper use of BioGlue. When the adhesive coating is thicker than 0.5-3.0 mm, as recommended by the manufacturer, it may predispose to the 'foreign body' reaction. Therefore, we suggest that BioGlue should be used restrictively, properly and only in potentially risky situations. Furthermore, the local infection may be present in the deep thoracic wound but may remain undetected by the standard tests. Therefore, the patients should be followed regularly because they may develop recurrent late wound complications.
6×3 cm, between the apex and the anterior thoracic wall (Fig. 1a ). An apical fistula between the left ventricular cavum and the described space was clearly excluded.
The treatment was similar for all three patients. The patient was re-operated upon in general anesthesia, the wound scar containing the cutaneous fistulous opening (in two patients) was excised, and the narrow fistulous canal leading towards the heart was removed. The space between the apex of the heart and the fascio-muscular layer of the anterior thoracic wall was filled with purulent-like content and dark-colored particles of BioGlue used at the time of primary TAVI. No pseudoaneurysm of the apex of the heart was found. The old sutures were completely removed from the apex including all Teflon or pericardial pledgets. Also, remnants of BioGlue were completely removed and local debridement of the wound was meticulously performed. Clinically, in the region of the heart apex and neighboring tissue, there were no signs of local infection but rather signs of a 'foreign body' reaction surrounded by healthy well-vascularized tissue. Although there was no bleeding and no dehiscence of the apical puncture site, and although any communication with the left ventricular cavity was completely excluded, the apex was mobilized and additionally secured with new polypropylene sutures (except in the first patient, who had revision on the 115th postoperative day, see Table 1 ). All material removed was sent for microscopic ( Fig.1b and c) and microbiological examination, together with additional smears from the apex and surrounding tissue. Then the wound was locally rinsed with povidone-iodine. Two small drains were placed into the space and the wound was closed primarily. The space was washed out by local irrigation with physiological solution for three days, and the drains were removed between the 4th and 7th day. The systemic antibiotic treatment was administered for one week.
Although preoperative superficial wound bacteriology showed P. fluorescens in one patient and in one skin flora (Table 1) , and despite evidence of purulent-like material at the time of wound debridement, all intraoperative cultures were sterile. The wounds healed 'per primam intentionem' and the patients' postoperative course was also completely uneventful. Echocardiography showed excellent valve function with no signs of endocarditis. Postoperative chest computed tomography (CT)-scan was performed in one patient and showed normal findings (Fig. 1d ).
Comment
BioGlue use is accompanied by reported side effects including phrenic nerve damage leading to diaphragmatic paralysis, false aneurysm, and local and distant complications from embolized particles but no side effects of BioGlue use in patients undergoing TAVI have yet been reported. A similar problem with wound healing after use of BioGlue has been already documented in pediatric and adult patients who underwent craniotomy [7] . It occurred weeks or months after the primary neurosurgical procedure.
BioGlue may predispose a patient to wound complications for several reasons. The local tissue reaction may be caused by its glutaraldehyde component which ensures that the BioGlue adheres to tissue. It can be cytotoxic and with BioGlue. During follow-up, a CT-scan (1 month postoperatively) showed no recurrence of fluid collection, and the patient is symptom-free.
BioGlue is commonly used in cardiovascular surgery and anecdotal reports plus experimental work has raised concerns about its adverse effects [3] .
Regarding its epicardial application, similar to our cases [1, 2] , and the anatomical relation to the phrenic nerve and conduction system (mainly in the aortic root area), we have to bear in mind that Lemaire et al. have experimentally proved that BioGlue can provoke diaphragmatic paralysis plus acute nerve injury and myocardial necrosis leading to sino-atrial node damage as well [4] .
In conclusion, we agree with the final comment by Pasic et al. about the necessity of clinical judgement and follow-up of patients with BioGlue.
